Skip to main content
. 2016 Oct 6;18:225. doi: 10.1186/s13075-016-1132-9

Fig. 3.

Fig. 3

Sarilumab increases OC, a marker of bone formation (nominal p = 0.057 vs placebo, week 52). MTX methotrexate, OC osteocalcin, (Q1,Q3) quartile 1 to quartile 3 interval, q2w every 2 weeks